Cancer Research UK has enrolled the first 240 patients in its Stratified Medicine Programme, designed to create a multi-gene testing panel for oncology drugs.

It is hoped that the £5.5m programme will aid the development of oncology drugs tailored to differing tumour characteristics, whereas a database of information on targeted cancer therapies will also be compiled.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Supported by both AstraZeneca and Pfizer, the programme plans to test up to 9,000 tumour samples to identify genetic markers in cancers including breast, bowel, lung, prostate, ovarian, and melanoma.

Medical staff from seven Experimental Cancer Medicine Centres across the UK will participate in the programme.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Imagene’s Oncology Intelligence (OI) Suite has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.

Discover the Impact